There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory agent with antitumor activity in non-Hodgkin lymphoma, with an acceptable toxicity profile and manageable side effects. A 79-year-old Caucasian male with non-germinal center B-cell-like DLBCL achieved complete remission (CR) after first-line treatment with seven out of eight scheduled cycles of a polychemotherapy containing anthracycline, which had to be discontinued early due to the onset of atrial fibrillation. After 5 months, the patient had an early epicardial relapse. He underwent lenalidomide considering age, cardiological comorbidities, and chronic renal failure. After the third cycle, he achieved CR, confirmed at restaging after the sixth cycle of treatment. Lenalidomide was safe and well tolerated in a patient with atrial fibrillation developed after an anthracycline-based regimen and a relapse of the DLBCL. Moreover, this regimen was effective in a case with a rare extranodal involvement of the epicardium.

1.
Siegel
R
,
Naishadham
D
,
Jemal
A
.
Cancer statistics, 2013
.
CA Cancer J Clin
.
2013
Jan
;
63
(
1
):
11
30
.
[PubMed]
0007-9235
2.
Vitolo
U
,
Seymour
JF
,
Martelli
M
,
Illerhaus
G
,
Illidge
T
,
Zucca
E
, et al;
ESMO Guidelines Committee
.
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2016
Sep
;
27
suppl 5
:
v91
102
.
[PubMed]
0923-7534
3.
Fanous
I
,
Dillon
P
.
Cancer treatment-related cardiac toxicity: prevention, assessment and management
.
Med Oncol
.
2016
Aug
;
33
(
8
):
84
.
[PubMed]
1357-0560
4.
Witzig
TE
,
Vose
JM
,
Zinzani
PL
,
Reeder
CB
,
Buckstein
R
,
Polikoff
JA
, et al
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
.
Ann Oncol
.
2011
Jul
;
22
(
7
):
1622
7
.
[PubMed]
0923-7534
5.
Zinzani
PL
,
Bendandi
M
,
Gherlinzoni
F
,
Mazza
P
,
Salvucci
M
,
Aitini
E
, et al
VNCOP-B regimen in the treatment of high-grade non-Hodgkin’s lymphoma in the elderly
.
Haematologica
.
1993
Nov-Dec
;
78
(
6
):
378
82
.
[PubMed]
0390-6078
6.
Crump
M
,
Neelapu
SS
,
Farooq
U
,
Van Den Neste
E
,
Kuruvilla
J
,
Westin
J
, et al
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
.
Blood
.
2017
Oct
;
130
(
16
):
1800
8
.
[PubMed]
0006-4971
7.
Gisselbrecht
C
,
Van Den Neste
E
.
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
.
Br J Haematol
.
2018
Sep
;
182
(
5
):
633
43
.
[PubMed]
0007-1048
8.
Skarbnik
AP
.
Current landscape for chimeric antigen receptor T cells in lymphomas
.
Curr Opin Hematol
.
2019
Nov
;
26
(
6
):
421
6
.
[PubMed]
1065-6251
9.
Chiappella
A
,
Castellino
A
,
Nicolosi
M
,
Santambrogio
E
,
Vitolo
U
.
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives
.
Expert Rev Hematol
.
2017
Apr
;
10
(
4
):
289
97
.
[PubMed]
1747-4086
10.
Zinzani
PL
,
Pellegrini
C
,
Gandolfi
L
,
Stefoni
V
,
Quirini
F
,
Derenzini
E
, et al
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial
.
Clin Lymphoma Myeloma Leuk
.
2011
Dec
;
11
(
6
):
462
6
.
[PubMed]
2152-2650
11.
Broccoli
A
,
Casadei
B
,
Chiappella
A
,
Visco
C
,
Tani
M
,
Cascavilla
N
, et al
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice
.
Oncologist
.
2019
Sep
;
24
(
9
):
1246
52
.
[PubMed]
1083-7159
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.